Zacks: Brokerages Anticipate Lannett Company, Inc. (NYSE:LCI) Will Announce Quarterly Sales of $132.27 Million
Equities analysts expect Lannett Company, Inc. (NYSE:LCI) to post $132.27 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Lannett’s earnings. The lowest sales estimate is $129.41 million and the highest is $134.60 million. Lannett reported sales of $193.72 million in the same quarter last year, which indicates a negative year-over-year growth rate of 31.7%. The company is expected to announce its next quarterly earnings report on Wednesday, February 5th.
On average, analysts expect that Lannett will report full-year sales of $534.99 million for the current financial year, with estimates ranging from $534.80 million to $535.17 million. For the next year, analysts forecast that the company will post sales of $595.60 million, with estimates ranging from $578.70 million to $612.99 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Lannett.
Lannett (NYSE:LCI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. Lannett had a negative net margin of 41.52% and a positive return on equity of 28.00%. The firm had revenue of $127.30 million during the quarter, compared to analysts’ expectations of $120.78 million. During the same period in the previous year, the company earned $0.44 earnings per share. Lannett’s quarterly revenue was down 17.9% compared to the same quarter last year.
Shares of NYSE:LCI opened at $8.93 on Friday. The company has a 50-day simple moving average of $11.84 and a 200-day simple moving average of $8.31. Lannett has a one year low of $4.33 and a one year high of $15.52. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.86 and a current ratio of 2.67. The stock has a market capitalization of $406.93 million, a price-to-earnings ratio of 3.80 and a beta of 2.22.
In other Lannett news, Director Patrick G. Lepore bought 25,000 shares of Lannett stock in a transaction dated Tuesday, September 3rd. The stock was acquired at an average cost of $9.82 per share, with a total value of $245,500.00. Following the completion of the acquisition, the director now owns 201,340 shares of the company’s stock, valued at $1,977,158.80. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Albert Paonessa III sold 16,195 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $12.54, for a total transaction of $203,085.30. Following the completion of the sale, the director now directly owns 45,945 shares of the company’s stock, valued at $576,150.30. The disclosure for this sale can be found here. 12.57% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of LCI. Glen Harbor Capital Management LLC purchased a new position in Lannett during the second quarter worth about $42,000. Tower Research Capital LLC TRC raised its holdings in Lannett by 312.5% during the third quarter. Tower Research Capital LLC TRC now owns 3,960 shares of the company’s stock worth $45,000 after purchasing an additional 3,000 shares in the last quarter. Aperio Group LLC purchased a new position in Lannett during the second quarter worth about $49,000. Tyers Asset Management LLC purchased a new position in Lannett during the second quarter worth about $58,000. Finally, Zacks Investment Management purchased a new position in Lannett during the second quarter worth about $65,000. 97.33% of the stock is owned by hedge funds and other institutional investors.
Lannett Company Profile
Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.
Read More: Short Selling Stocks and Day Traders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.